ZS:NASDAQ
Zscaler, Inc.
Data as of 2026-03-11 - not real-time
$156.61
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Zscaler’s stock is trading at $156.61, well below its DCF‑derived fair value of $252.78, implying roughly 50% upside. The 20‑day SMA sits at 161.74 and the 50‑day at 190.29, with price under both, confirming a short‑term bearish positioning. RSI at 40.7 indicates neither overbought nor oversold conditions. MACD shows a bullish histogram (+2.48) despite the overall bearish trend, hinting at potential momentum reversal. Volatility is elevated at 74.8% over 30 days and beta of 1.25, suggesting price swings will be pronounced. Fundamentals reveal 26% YoY revenue growth, a robust 76.6% gross margin, but operating and profit margins remain negative. Cash on hand ($3.51 bn) exceeds debt ($1.87 bn), giving the company a solid liquidity cushion.
Analysts are overwhelmingly positive, with 46 covering the stock and a consensus “Buy” rating; recent upgrades from Bernstein and an Overweight call from Wells Fargo with a $200 price target reinforce optimism. The latest quarter delivered record revenue of $816 million, beating expectations and supporting the growth narrative. The forward PE of 34 is in line with the industry average of 36.85, while the price‑to‑book of 11.45 reflects a premium valuation but still below the DCF target. No dividend is paid, so income‑focused investors should not rely on yield. The stock sits near its identified support at $140.56 and well below the resistance at $179.90, offering a technical entry point. Given the combination of strong cash flow, expanding enterprise adoption, and a sizable valuation gap, the investment case leans toward a growth‑oriented buy. Investors should, however, be prepared for heightened price volatility in the near term.
Analysts are overwhelmingly positive, with 46 covering the stock and a consensus “Buy” rating; recent upgrades from Bernstein and an Overweight call from Wells Fargo with a $200 price target reinforce optimism. The latest quarter delivered record revenue of $816 million, beating expectations and supporting the growth narrative. The forward PE of 34 is in line with the industry average of 36.85, while the price‑to‑book of 11.45 reflects a premium valuation but still below the DCF target. No dividend is paid, so income‑focused investors should not rely on yield. The stock sits near its identified support at $140.56 and well below the resistance at $179.90, offering a technical entry point. Given the combination of strong cash flow, expanding enterprise adoption, and a sizable valuation gap, the investment case leans toward a growth‑oriented buy. Investors should, however, be prepared for heightened price volatility in the near term.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- price near technical support and below key moving averages
- recent analyst upgrades and $200 target from Wells Fargo
- bullish MACD histogram hinting at momentum shift
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 26% YoY revenue growth and strong gross margins
- substantial cash cushion relative to debt
- valuation gap of ~50% versus DCF fair value
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- secular demand for cloud security and Zero Trust solutions
- record Q2 revenue and expanding enterprise adoption
- undervalued position relative to long‑term fair value estimate
Key Metrics & Analysis
Financial Health
Revenue Growth25.90%
Profit Margin-2.25%
P/E Ratio34.1
ROE-3.56%
ROA-1.41%
Debt/Equity85.00
P/B Ratio11.5
Op. Cash Flow$1.1B
Free Cash Flow$1.0B
Industry P/E36.8
Technical Analysis
TrendBearish
RSI40.7
Support$140.56
Resistance$179.90
MA 20$161.74
MA 50$190.29
MA 200$262.72
MACDBullish
VolumeIncreasing
Fear & Greed Index76.91
Valuation
Fair Value$252.78
Target Price$234.79
Upside/Downside49.92%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.25
Volatility74.81%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
More Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.